Human Leukemia Cell THP-1 based Proliferation Assay Service
The Creative Biolabs service provides definitive, quantifiable data using the THP-1 cell line, a powerful model for human monocytes. This approach creates a crucial bridge between a theoretical mechanism and a quantitative biological effect, essential for candidates targeting hematological malignancies and immunomodulation. We deliver specific, quantifiable outcomes—not just raw data—to ensure a clear go/no-go decision point for your drug candidate by precisely determining its potency, mechanism of action, and therapeutic window within a relevant human context.
Background What We Can Offer Workflow Why Choose Us FAQs Customer Review Related Services Contact Us
The Strategic Value of the THP-1 Model
The THP-1 cell line, derived from human acute monocytic leukemia, is an indispensable and highly relevant model for studying the immune system in oncology. Its monocyte/macrophage mimicry—especially its ability to differentiate into adherent, macrophage-like cells using agents like phorbol 12-myristate 13-acetate (PMA)—makes it ideal for investigating compounds that modulate monocyte function and subsequent immune responses. By simulating these crucial biological responses in vitro, THP-1 provides a foundational link to expected in vivo activity, significantly reducing the risk of later-stage failures for drug candidates and immunomodulators.
Key Deliverables and Problem-Solving Capabilities
The THP-1 model is dynamic, exhibiting phenotypic plasticity that can lead to drug resistance, a critical challenge in cancer therapy. Our advanced services are designed to specifically address this complexity, moving beyond simple viability scores.
Addressing Phenotype Shifts
We use flow cytometry/high-content imaging (with PI, Calcein AM, Ki-67) to differentiate true proliferative inhibition from macrophage-like differentiation, which can increase resistance to agents like TRAIL.
Resistance Mechanism Identification
Our platform analyzes changes in crucial surface receptors (e.g., down-regulation of DR4/DR5), ensuring candidates are evaluated against biologically relevant resistance mechanisms.
Contact our team today to request a consultation and discuss how our cutting-edge THP-1 assays can provide the decisive data you need to drive your next therapeutic breakthrough.
Workflow
Our detailed, transparent workflow ensures robust, reproducible results suitable for integration into regulatory submissions:
Why Choose Us
Creative Biolabs' differentiation lies in our specialized expertise and proprietary protocols for the monocyte lineage. Our THP-1 assays provide deep mechanistic insight beyond simple viability. We use advanced flow cytometry for mechanistic differentiation, accurately dissecting the delicate balance between cytotoxicity and phenotypic shift (e.g., macrophage differentiation). Furthermore, our drug resistance expertise utilizes proprietary protocols to test candidates against drug-resistant THP-1 sublines, addressing the critical clinical challenge of therapeutic relapse. Our established paradigms ensure robust data with strong predictive power, bridging the gap between in vitro observation and in vivo success.
If your project requires advanced resistance modeling or complex phenotypic analysis, we encourage you to connect with our scientific team immediately to discuss a custom assay design.
FAQs
Q: How do you distinguish between cytotoxicity (cell death) and differentiation?
A: We go beyond standard viability assays. Our approach uses confirmatory methods like flow cytometry with specialized markers to ensure we are accurately measuring true cytotoxicity rather than a phenotypic shift that arrests proliferation.
Q: Can the assay be used for combination drug testing?
A: Absolutely. Our platform is optimized for complex compound treatment paradigms, including testing combinations of two or more agents to determine synergistic or additive effects. We recommend sharing your desired dose matrix and experimental goals during the initial consultation phase.
Q: Do you offer assays for testing compounds against drug-resistant THP-1 cells?
A: Yes, Creative Biolabs specializes in this critical area. We can generate, characterize, and profile sublines resistant to your specific compound or a known standard-of-care agent. This is invaluable for identifying compounds effective against relapsed disease.
Customer Review
-
Phenotype Clarity
Using Creative Biolabs' THP-1 proliferation assay in our research has significantly improved the differentiation between cytotoxic effects and PMA-induced macrophage differentiation, crucial for our TRAIL studies. – Kate J*nes
-
Resistance Modeling
Using Creative Biolabs' THP-1 proliferation assay in our research has significantly facilitated our ability to generate and profile drug-resistant sublines, which allowed us to identify cross-resistance patterns earlier than expected. – Anna L*pez
Related Services
To fully characterize your therapeutic candidate's interaction with the immune system and cancer, consider these complementary services offered by Creative Biolabs:
Macrophage Immunophenotyping Service
Creative Biolabs' macrophage immunophenotyping service uses advanced multicolor flow cytometry to precisely characterize macrophage subsets (M1/M2) based on surface markers for deep immunological insights.
Learn More →
Chemokine Production Measurement Service
Creative Biolabs offers chemokine production assays using multiple techniques (qPCR, ELISA, flow cytometry) to identify and manipulate chemokine signaling pathways for IO target identification.
Learn More →
Contact Us
Creative Biolabs offers the industry-leading human leukemia cell THP-1 based proliferation assay service, providing precise GI50 and LC50 data, advanced mechanistic profiling, and expert modeling of drug resistance. We provide the high-fidelity data you need to confidently advance your immuno-oncology drug discovery efforts.
To discuss your specific project requirements, customized assay design, or complex compound screening needs, please reach out to our team today.
